missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CDK9 Monoclonal Antibody (K.513.1)

Description
It is not recommended to aliquot this antibody.
CDK9 is a serine/threonine kinase which when complexed with CyclinT1 forms an active holoenzyme complex. This complex plays a key role in regulating the eukaryotic cell cycle. CDK9 is coexpressed and copurified with CyclinT1. CDK9 regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors. CDK9 promotes RNA synthesis in genetic programs for cell growth, differentiation, and viral pathogenesis. The CDK9/cyclin-K complex also has kinase activity towards CTD of RNAPII and can substitute for CDK9/cyclin-T P-TEFb in vitro. Chronic activation of CDK9 causes cardiac myocyte enlargement leading to cardiac hypertrophy and confers a predisposition to heart failure.
Specifications
Specifications
| Antigen | CDK9 |
| Applications | Flow Cytometry, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot, Immunocytochemistry |
| Classification | Monoclonal |
| Clone | K.513.1 |
| Concentration | 163 μg/mL |
| Conjugate | Unconjugated |
| Formulation | 0.01M HEPES with 100μg/mL BSA, 50% glycerol, 0.15M NaCl and <0.02% sodium azide; pH 7.5 |
| Gene | CDK9 |
| Gene Accession No. | P50750, Q5EAB2, Q641Z4, Q99J95 |
| Gene Alias | C-2k; CDC2L4; CDC2-related kinase; Cdk9; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; CTK1; cyclin dependent kinase 9; cyclin-dependent kinase 9; cyclin-dependent kinase 9 (CDC2-related kinase); PITALRE; RP11-228B15.5; serine/threonine protein kinase PITALRE; Serine/threonine-protein kinase PITALRE; TAK; Tat-associated kinase complex catalytic subunit |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?